SCHEMBL13629773

SCHEMBL13629773

CCc1ccc(NS(=O)(=O)c2ccccc2OC)cc1C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.57
NPSR1 Q6W5P4 1/20 0.57
BRD4 O60885 7/20 0.57
BRD1 O95696 1/20 0.57
BRPF1 P55201 1/20 0.57
SLC22A12 Q96S37 1/20 0.55
PKM P14618 2/20 0.54
SMN1; SMN2 Q16637 3/20 0.52
TSHR P16473 1/20 0.52
CASP1 P29466 1/20 0.52
CASP7 P55210 1/20 0.52
HSD17B10 Q99714 1/20 0.52
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
PTPN2 P17706 2/20 0.50
PTPN1 P18031 2/20 0.50
PTPN5 P54829 2/20 0.50
HSPD1 P10809 1/20 0.50
HSPE1 P61604 1/20 0.50
BRD2 P25440 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13853028 0.86 SLC22A12 (0.54) BRD4BRD1BRPF1SLC22A12PKM
SCHEMBL13629415 0.85 MEN1 (0.57) ALDH1A1BRD4SLC22A12PKMSMN1; SMN2
SCHEMBL13629464 0.85 ALDH1A1 (0.77) ALDH1A1NPSR1SMN1; SMN2MEN1KMT2A
SCHEMBL13615295 0.82 ALDH1A1 (0.57) ALDH1A1NPSR1BRD4BRD1BRPF1
SCHEMBL13629320 0.81 SLC22A12 (0.54) ALDH1A1BRD4SLC22A12MEN1KMT2A
SCHEMBL13629311 0.78 SLC22A12 (0.62) BRD4SLC22A12
SCHEMBL13853032 0.78 SLC22A12 (0.58) SLC22A12
SCHEMBL7569855 0.77 SLC22A12 (0.58) ALDH1A1NPSR1BRD4BRD1BRPF1
SCHEMBL7364604 0.77 CA12 (0.59) ALDH1A1BRD4SLC22A12PKMSMN1; SMN2
SCHEMBL13629401 0.76 ALDH1A1 (0.65) ALDH1A1BRD4SLC22A12PKMMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-11-05 US disclosed
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors NOVARTIS AG 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118277-A1 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK ALDH1A1 2057/4885NPSR1 3787/4885BRD4 548/4885
US-20090275593-A1 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors TIE1, TEK, MATK ALDH1A1 2121/4885NPSR1 4042/4885BRD4 674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.